title: Treatment of pharyngeal non-Hodgkin lymphoma in a patient with Wiskott-Aldrich syndrome.
abstract: Wiskott-Aldrich syndrome (WAS) is characterized by primary immunodeficiency, thrombocytopenia and eczema. Patients with WAS have an increased risk to develop tumors. Non-Hodgkin lymphoma (NHL) represents the most common malignancy occurring in WAS-affected patients, diffuse-large-B-cell lymphoma is the most frequently encountered variant. We describe a case of a patient with WAS and NHL in the pharynx, an atypical tumor site presentation. The patient was successfully treated with a reduced dose chemotherapy regimen plus anti-CD20 monoclonal antibody. He is in complete remission 3 years from the start of treatment.
authors: Division of Pediatric Oncology, Catholic University of Rome, Rome, Italy.
authors: Paola
authors: P
authors: Coccia
authors: Stefano
authors: S
authors: Mastrangelo
authors: Antonio
authors: A
authors: Ruggiero
authors: Maria
authors: M
authors: Scalzone
authors: Angelo
authors: A
authors: Rosolen
authors: Palma
authors: P
authors: Maurizi
authors: Riccardo
authors: R
authors: Riccardi
mesh_terms: D000293:Adolescent; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000209:etiology*; D008297:Male; D012074:Remission Induction; D000069283:Rituximab; D014923:Wiskott-Aldrich Syndrome / Q000150:complications*
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab